Because GPNMB levels were only increased in CSF from GRN mutation carriers, but not C9 or MAPT cases, GPNMB levels could serve as a biomarker to differentiate between FTD caused by GRN mutantions or other FTD genes. Here, C9 is linked to frontotemporal dementia.